Skip to Main Content

When will AI replace your radiologist? What can pharma learn from ketamine? And is liver disease more complicated than anyone thought?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, our colleague Matthew Herper joins us to pick apart Gilead Sciences’ recent failure in the pervasive liver disease NASH and what it means for the many similar efforts in the pipeline. Then, STAT’s Megan Thielking stops by to talk about what could be the first novel treatment for depression in more than three decades, a ketamine-related drug from Johnson & Johnson. Later we hear from Dr. Eric Topol, a cardiologist and geneticist at the Scripps Research Institute in San Diego, about the chasm between hype and reality when it comes to AI in medicine. And then we bring you a lightning round, featuring the latest CRISPR patent drama, 2019’s crop of biotech IPOs, and a new term of art to in the biotech lexicon.


For more on what we cover, here’s the Gilead news; here’s the latest on J&J’s depression drug; and here’s a transcript of the Topol interview.

We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on iTunes, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].


Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].